Form D · Biotechnology
PeproMene Bio, Inc.
Irvine, CA · CIK 0001742221
Offering snapshot reported Jun 12, 2018 · SEC filing
- Reported sold
- $40.2M Offering amount: $40.2M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $1K Reported outside-investor minimum
- First sale
- Jul 17, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2018 | Initial | $40,210,134 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-314371
Source: Form D, filed Jun 12, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Young Rae Choi | Director |
| Sun Tae Hwang | Director |
| Hong Woo Kim | Director, Executive |
| Hyukjong Lee | Director |
| Yung Ki Park | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Spectrum Center Dr. Suite 4034
Irvine, CA, 92618
Irvine, CA, 92618